These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 7733123

  • 1. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.
    Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH.
    Bone; 1996 Feb; 18(2):207-12. PubMed ID: 8833216
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E.
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
    Reginster JY, Meurmans L, Deroisy R, Jupsin I, Biquet I, Albert A, Franchimont P.
    Eur J Clin Invest; 1994 Aug; 24(8):565-9. PubMed ID: 7982445
    [Abstract] [Full Text] [Related]

  • 10. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
    Tascioglu F, Colak O, Armagan O, Alatas O, Oner C.
    Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
    [Abstract] [Full Text] [Related]

  • 11. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS, Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 13. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 14. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.
    Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, Whitehead MI, Stevenson JC.
    Calcif Tissue Int; 1996 Jul; 59(1):6-11. PubMed ID: 8661976
    [Abstract] [Full Text] [Related]

  • 15. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
    Gennari C, Agnusdei D, Montagnani M, Gonnelli S, Civitelli R.
    Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
    [Abstract] [Full Text] [Related]

  • 16. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R, Sigaud A, Azria M, Herrmann FR.
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [Abstract] [Full Text] [Related]

  • 17. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 18. [Effect of low calcitonin doses on bone remodeling in postmenopausal women with high bone turnover rate].
    Campusano C, López JM, Campino C, Cárdenas I, Rojas A.
    Rev Med Chil; 2000 Apr; 128(4):387-91. PubMed ID: 10962855
    [Abstract] [Full Text] [Related]

  • 19. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
    Grigoriou O, Papoulias I, Vitoratos N, Papadias C, Konidaris S, Antoniou G, Chryssikopoulos A.
    Maturitas; 1997 Dec 15; 28(2):147-51. PubMed ID: 9522322
    [Abstract] [Full Text] [Related]

  • 20. Effect of different doses of nasal salmon calcitonin on bone mass.
    Thamsborg G, Storm TL, Sykulski R, Brinch E, Nielsen HK, Sørensen OH.
    Calcif Tissue Int; 1991 May 15; 48(5):302-7. PubMed ID: 2054714
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.